- Home
- LDTC vs INTS Comparison
LDTC vs INTS Comparison
Compare LDTC & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDTC
- INTS
- Stock Information
- Founded
- LDTC 2007
- INTS 2012
- Country
- LDTC Canada
- INTS United States
- Employees
- LDTC N/A
- INTS N/A
- Industry
- LDTC Blank Checks
- INTS Biotechnology: Pharmaceutical Preparations
- Sector
- LDTC Finance
- INTS Health Care
- Exchange
- LDTC Nasdaq
- INTS Nasdaq
- Market Cap
- LDTC 37.5M
- INTS 35.3M
- IPO Year
- LDTC N/A
- INTS 2023
- Fundamental
- Price
- LDTC $0.52
- INTS $2.21
- Analyst Decision
- LDTC Buy
- INTS Strong Buy
- Analyst Count
- LDTC 2
- INTS 3
- Target Price
- LDTC $3.00
- INTS $8.50
- AVG Volume (30 Days)
- LDTC 247.3K
- INTS 23.6K
- Earning Date
- LDTC 02-12-2025
- INTS 03-21-2025
- Dividend Yield
- LDTC N/A
- INTS N/A
- EPS Growth
- LDTC N/A
- INTS N/A
- EPS
- LDTC N/A
- INTS N/A
- Revenue
- LDTC $331,997.00
- INTS N/A
- Revenue This Year
- LDTC $1,128.94
- INTS N/A
- Revenue Next Year
- LDTC $169.93
- INTS N/A
- P/E Ratio
- LDTC N/A
- INTS N/A
- Revenue Growth
- LDTC 141.86
- INTS N/A
- 52 Week Low
- LDTC $0.22
- INTS $1.50
- 52 Week High
- LDTC $4.04
- INTS $5.78
- Technical
- Relative Strength Index (RSI)
- LDTC 34.72
- INTS 47.88
- Support Level
- LDTC $0.42
- INTS $2.15
- Resistance Level
- LDTC $0.61
- INTS $2.40
- Average True Range (ATR)
- LDTC 0.09
- INTS 0.20
- MACD
- LDTC -0.01
- INTS 0.01
- Stochastic Oscillator
- LDTC 23.15
- INTS 52.50
About LDTC LeddarTech Holdings Inc.
LeddarTech Holdings Inc is a company that develops and provides comprehensive perception software solutions that enable the deployment of ADAS and autonomous driving (AD) applications. Its automotive-grade software applies AI and computer vision algorithms to generate accurate 3D models of the environment, allowing for decision-making and safer navigation. The company generates the majority of its revenue from France, Canada, and the United states.
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with major unmet medical need.